This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1dbk
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| + | |||
==MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY== | ==MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY== | ||
<StructureSection load='1dbk' size='340' side='right' caption='[[1dbk]], [[Resolution|resolution]] 3.00Å' scene=''> | <StructureSection load='1dbk' size='340' side='right' caption='[[1dbk]], [[Resolution|resolution]] 3.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[1dbk]] is a 2 chain structure | + | <table><tr><td colspan='2'>[[1dbk]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1DBK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1DBK FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ANO:5-BETA-ANDROSTANE-3,17-DIONE'>ANO</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ANO:5-BETA-ANDROSTANE-3,17-DIONE'>ANO</scene></td></tr> | ||
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1dbk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1dbk OCA], [http://pdbe.org/1dbk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1dbk RCSB], [http://www.ebi.ac.uk/pdbsum/1dbk PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1dbk FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1dbk OCA], [http://pdbe.org/1dbk PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1dbk RCSB], [http://www.ebi.ac.uk/pdbsum/1dbk PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=1dbk ProSAT]</span></td></tr> |
</table> | </table> | ||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
| Line 14: | Line 15: | ||
<text>to colour the structure by Evolutionary Conservation</text> | <text>to colour the structure by Evolutionary Conservation</text> | ||
</jmolCheckbox> | </jmolCheckbox> | ||
| - | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/ | + | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1dbk ConSurf]. |
<div style="clear:both"></div> | <div style="clear:both"></div> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 27: | Line 28: | ||
==See Also== | ==See Also== | ||
| - | *[[ | + | *[[3D structures of antibody|3D structures of antibody]] |
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| - | [[Category: Lk3 transgenic mice]] | ||
[[Category: Arevalo, J H]] | [[Category: Arevalo, J H]] | ||
[[Category: Wilson, I A]] | [[Category: Wilson, I A]] | ||
[[Category: Immunoglobulin]] | [[Category: Immunoglobulin]] | ||
Revision as of 04:14, 30 August 2017
MOLECULAR BASIS OF CROSS-REACTIVITY AND THE LIMITS OF ANTIBODY-ANTIGEN COMPLEMENTARITY
| |||||||||||
